5/13/2015 10:59:50 AM
BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX), a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, today announced the appointment of Abbie Celniker, Ph.D., to its Board of Directors.
"Abbie brings nearly three decades of business and scientific leadership in the biotechnology and pharmaceutical industries to Dyax, with a proven track record of successfully developing and commercializing life science products," said Henry E. Blair, Chairman of Dyax's Board of Directors.